Impact BioMedical Inc. 2025年度报告

Form 10-K ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or IMPACT BIOMEDICAL INC. (Exact name of registrant as specified in its charter) Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer as defined in Rule 405 of the Securities Act. YES☐NO☒ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. YES☐NO☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company or an emerging growth company. See definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting Large Accelerated Filer☐Non-Accelerated Filer☒ Accelerated Filer☐Smaller Reporting Company☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectivenessof its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registeredpublic accounting firm that prepared or issued its audit report. Yes☐No☐ Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Act). Yes☐No☒ If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of theregistrant included in the filing reflect the correction of an error to previously issued financial statements.☐ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-basedcompensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to § 240.10D-1(b).☐ The aggregate market value of the registrant’s common stock held by non-affiliates of the registrant computed by reference to the priceat which the common stock was last sold, as reported on the NYSE American LLC exchange on June 30, 2025 was $7,599,000. As of March 6, 2026, there were 107,821,231 shares of the registrant’s common stock, $0.001 par value, outstanding. DOCUMENTS INCORPORATED BY REFERENCE None. ITEM 1BUSINESS3ITEM 1ARISK FACTORS7ITEM 1BUNRESOLVED STAFF COMMENTS16ITEM 2PROPERTIES16ITEM 3LEGAL PROCEEDINGS16ITEM 4MINE SAFETY DISCLOSURES16 PART I ITEM 1 - BUSINESS Overview Impact Biomedical Inc. (“IBO”. “Impact”, “Impact BioMedical”, “we”, “us”, “our” or the “Company”) discovers, confirms, andpatents unique science and technologies which can be developed into new offerings in human healthcare and wellness in collaborationwith external partners through licensing, co-development, joint ventures, and other relationships, and currently trades on the NYSE By leveraging technology and new science with strategic partnerships, we provide advances in biopharmaceuticals, over the counterdirect to consumer wellness offerings, and drug discovery for the prevention, inhibition, and treatment of neurological, oncologic, andinflammatory diseases. In addition to our existing efforts, we continually search for, and evaluate, other potential new offerings to add Our business model includes partnering and potentially direct sales for commercialization and distribution. Potential licensors anddevelopment partners include pharmaceutical, consumer packaged goods companies and others, who would commercialize IBOtechnologies in exchange for milestone, and royalty payments. Currently, our operations are conducted, and our assets are ownedthrough our principal subsidiaries: (i) Global BioLife, Inc. (“Global BioLife”), which was incorporated on April 14, 2017, (ii) ImpactBioLife Science, Inc. (“Impact BioLife”), which was incorporated on August 28, 2020, (iii) Global BioMedical, Inc. (“Global In addition to our existing efforts, we continually search and evaluate other potential new offerings to add to our portfolio. Below is a list of our principal subsidiaries: Impact BioLife Science, Inc.We are the sole owner of the issued and outstanding common stock of Impact BioLife Science, Inc. Global BioLife, Inc